Vertex Pharmaceuticals, Inc. (VRTX)
504.73
-2.01
(-0.40%)
USD |
NASDAQ |
Oct 02, 16:00
505.10
+0.37
(+0.07%)
Pre-Market: 20:00
Vertex Pharmaceuticals Gross Profit Margin (Quarterly) : 85.37% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 85.37% |
| March 31, 2026 | 86.96% |
| December 31, 2025 | 85.56% |
| September 30, 2025 | 86.69% |
| June 30, 2025 | 86.35% |
| March 31, 2025 | 86.78% |
| December 31, 2024 | 85.34% |
| September 30, 2024 | 85.85% |
| June 30, 2024 | 85.88% |
| March 31, 2024 | 87.25% |
| December 31, 2023 | 85.40% |
| September 30, 2023 | 87.15% |
| June 30, 2023 | 87.58% |
| March 31, 2023 | 88.66% |
| December 31, 2022 | 87.41% |
| September 30, 2022 | 87.25% |
| June 30, 2022 | 87.83% |
| March 31, 2022 | 88.17% |
| December 31, 2021 | 88.01% |
| September 30, 2021 | 88.11% |
| June 30, 2021 | 87.41% |
| March 31, 2021 | 88.95% |
| December 31, 2020 | 87.61% |
| September 30, 2020 | 87.95% |
| June 30, 2020 | 87.85% |
| Date | Value |
|---|---|
| March 31, 2020 | 89.21% |
| December 31, 2019 | 86.84% |
| September 30, 2019 | 85.96% |
| June 30, 2019 | 85.45% |
| March 31, 2019 | 88.83% |
| December 31, 2018 | 85.84% |
| September 30, 2018 | 85.79% |
| June 30, 2018 | 86.17% |
| March 31, 2018 | 88.82% |
| December 31, 2017 | 87.10% |
| September 30, 2017 | 87.40% |
| June 30, 2017 | 86.87% |
| March 31, 2017 | 93.43% |
| December 31, 2016 | 86.81% |
| September 30, 2016 | 86.93% |
| June 30, 2016 | 89.52% |
| March 31, 2016 | 87.28% |
| December 31, 2015 | 84.59% |
| September 30, 2015 | 89.68% |
| June 30, 2015 | 89.85% |
| March 31, 2015 | 85.21% |
| December 31, 2014 | 84.65% |
| September 30, 2014 | 87.34% |
| June 30, 2014 | 87.50% |
| March 31, 2014 | 80.27% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Gilead Sciences, Inc. | 79.81% |
| Sionna Therapeutics, Inc. | -- |
| Regeneron Pharmaceuticals, Inc. | 83.68% |
| Ionis Pharmaceuticals, Inc. | 96.13% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 23.74% |
| Return on Assets | 17.08% |
| Return on Invested Capital | 21.57% |
| Profit Margin (Quarterly) | 32.89% |
| Operating Margin (Quarterly) | 38.24% |
| Return on Net Operating Assets | 53.20% |